Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice

Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function indb/dbmice

(2013) T Nagata et al.   BRITISH JOURNAL OF PHARMACOLOGY

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

(2013) David Z.I. Cherney et al.   CIRCULATION

Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus

(2013) L. H. Chen et al.   DIABETES OBESITY & METABOLISM

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice

(2013) Atsuo Tahara et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

SGLT2 inhibitors enter crowded diabetes space

(2013) Aaron Bouchie   NATURE BIOTECHNOLOGY

Mechanisms of Diabetic Complications

(2013) Josephine M. Forbes et al.   PHYSIOLOGICAL REVIEWS

Effects of Combining Linagliptin Treatment with BI-38335, A Novel SGLT2 Inhibitor, on Pancreatic Islet Function and Inflammation in db/db Mice

(2012) L. Chen et al.   CURRENT MOLECULAR MEDICINE

Dapagliflozin

(2012) Greg L. Plosker   DRUGS

Activation of Liver X Receptor Inhibits Osteopontin and Ameliorates Diabetic Nephropathy

(2012) H. Tachibana et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Managing Chronic Inflammation in the Aging Diabetic Patient With CKD by Diet or Sevelamer Carbonate: A Modern Paradigm Shift

(2012) H. Vlassara et al.   JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus

(2012) Jean Whaley et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

A Glimpse of Various Pathogenetic Mechanisms of Diabetic Nephropathy

(2011) Yashpal S. Kanwar et al.   Annual Review of Pathology-Mechanisms of Disease

Activation of Peroxisome Proliferator–Activated Receptor δ Inhibits Streptozotocin-Induced Diabetic Nephropathy Through Anti-Inflammatory Mechanisms in Mice

(2011) Yuichi Matsushita et al.   DIABETES

SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function

(2011) Michael J. Jurczak et al.   DIABETES

Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes

(2011) R. Kodera et al.   DIABETOLOGIA

High Glucose Increases Metallothionein Expression in Renal Proximal Tubular Epithelial Cells

(2011) Daisuke Ogawa et al.   Experimental Diabetes Research

Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy

(2011) Juan F. Navarro-González et al.   Nature Reviews Nephrology

Oxidative Stress and Diabetic Complications

(2010) Ferdinando Giacco et al.   CIRCULATION RESEARCH

The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats

(2010) F. R. Macdonald et al.   DIABETES OBESITY & METABOLISM

SGLT2 inhibition — a novel strategy for diabetes treatment

(2010) Edward C. Chao et al.   NATURE REVIEWS DRUG DISCOVERY

Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats

(2008) S. Han et al.   DIABETES

Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models

(2008) Y. Fujimori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS